Serum protein profile of Crohn's disease treated with infliximab (original) (raw)
Pharmacogénétique de l’infliximab dans la maladie de Crohn
Vinciane Dideberg
Acta Endoscopica, 2007
View PDFchevron_right
Infliximab Exposure Associates With Radiologic Evidence of Healing in Patients With Crohn’s Disease
Philippe Van Hootegem
Clinical Gastroenterology and Hepatology, 2020
View PDFchevron_right
Open-label infliximab therapy in Crohn's disease: a long-term multicenter study of efficacy, safety and predictors of response
Antonio Lopez-sanromán
Gastroenterología y Hepatología, 2008
View PDFchevron_right
Retreatment and maintenance therapy with infliximab in fistulising Crohn's disease
ruth de francisco
Gastroenterology, 2003
View PDFchevron_right
Monitoring a Combination of Calprotectin and Infliximab Identifies Patients With Mucosal Healing of Crohn’s Disease
guy lambrecht
Clinical Gastroenterology and Hepatology, 2020
View PDFchevron_right
The duration of effect of infliximab maintenance treatment in paediatric Crohn’s disease is limited
Lissy Ridder
Alimentary Pharmacology & Therapeutics, 2010
View PDFchevron_right
Induction Therapy With Biosimilar Infliximab in Children With Crohn Disease
Rizal Ardiansyah
Journal of Pediatric Gastroenterology & Nutrition, 2017
View PDFchevron_right
Higher Postinduction Infliximab Serum Trough Levels Are Associated With Healing of Fistulizing Perianal Crohn’s Disease in Children
Eytan Wine
Inflammatory Bowel Diseases
View PDFchevron_right
Infliximab reverses growth hormone resistance associated with inflammatory bowel disease
Antonio Picardi
Alimentary Pharmacology and Therapeutics, 2005
View PDFchevron_right
Distinct Thresholds of Infliximab Trough Level Are Associated with Different Therapeutic Outcomes in Patients with Inflammatory Bowel Disease
Nicolas Williet
Inflammatory Bowel Diseases, 2017
View PDFchevron_right
Evaluation of inflammatory activity in Crohn’s disease and ulcerative colitis
Maria de Lourdes Abreu Ferrari
World Journal of Gastroenterology, 2012
View PDFchevron_right
Efficacy and safety of infliximab induction therapy in Crohn's Disease in Central Europe - a Hungarian nationwide observational study
Csaba Dr Balázs
BMC Gastroenterology, 2009
View PDFchevron_right
Infliximab and the risk of latent viruses reactivation in active Crohnʼs disease
Massimiliano Bergallo
Inflammatory Bowel Diseases, 2007
View PDFchevron_right
Treatment Persistence for Infliximab Versus Adalimumab in Crohnʼs Disease
Pablo Olivera
Inflammatory Bowel Diseases, 2017
View PDFchevron_right
Infliximab Therapy in 30 Patients With Refractory Pediatric Crohn Disease With and Without Fistulas in The Netherlands
Lissy Ridder
Journal of Pediatric Gastroenterology and Nutrition, 2004
View PDFchevron_right
Fibrotic Strictures and Anti-TNF-α Therapy in Crohn’s Disease
Giovanni Terrosu
Digestion, 2007
View PDFchevron_right
Diagnosis and assessment of Crohns disease: The present and the future
Giovanni Terrosu
Expert Review of Gastroenterology and Hepatology, 2010
View PDFchevron_right
Crohn’s disease in women
Ivana Plavsic
International Journal of Women's Health, 2013
View PDFchevron_right
692 Impact of Body Mass Index on Efficacy of Infliximab in Children With Inflammatory Bowel Disease
Shehzad Saeed
Gastroenterology, 2013
View PDFchevron_right
Inflammatory Bowel Disease. From Bench to Bedside
Fergus Shanahan
Digestive and Liver Disease, 2004
View PDFchevron_right
What is the importance of anti-TNF agents in the treatment of luminal (inflammatory type) Crohn's disease?
Gökhan Kabaçam
The Turkish Journal of Gastroenterology, 2010
View PDFchevron_right
The efficacy and safety of a third anti-TNF monoclonal antibody in Crohnâs disease after failure of two other anti-TNF antibodies
P. Michetti
Alimentary Pharmacology & Therapeutics, 2010
View PDFchevron_right
Evaluation of Infliximab Effects on Gastrointestinal Bleeding in Crohn’s Disease Using Double-Balloon Endoscopy
Toshimi Chiba
Case Reports in Gastroenterology, 2009
View PDFchevron_right
New serological markers in pediatric patients with inflammatory bowel disease
Márta Kovács
World Journal of Gastroenterology, 2014
View PDFchevron_right
Combination of genetic and quantitative serological immune markers are associated with complicated Crohnʼs disease behavior
Emil Chuang
Inflammatory Bowel Diseases, 2011
View PDFchevron_right
When to use biological agents in inflammatory bowel disease
Rupert Leong
Journal of Gastroenterology and Hepatology, 2012
View PDFchevron_right
Response to infliximab treatment in Crohn's disease is not associated with mutations in the CARD15 (NOD2) gene: an analysis in 534 patients from two multicenter, prospective GCP-level trials
Peter Croucher
2002
View PDFchevron_right
P704 Do antiglycan antibodies have an impact on the course of Crohn's disease?
Bulent Baban
Journal of Crohn's and Colitis, 2013
View PDFchevron_right
Arthritis or vasculitis as presenting symptoms of Crohn’s disease
Ori Segol
Rheumatology International, 2005
View PDFchevron_right
European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis
N. Mortensen
Gut, 2006
View PDFchevron_right
Changes in Serum Trough Levels of Infliximab During Treatment Intensification but not in Anti-infliximab Antibody Detection are Associated with Clinical Outcomes after Therapeutic Failure in Crohn's Disease
Klaus Bendtzen
Journal of Crohn's & colitis, 2015
View PDFchevron_right
Behaviour of Crohn's disease according to the Vienna classification
David Sachar
Gut, 2002
View PDFchevron_right
Antibodies to Infliximab Are Associated with Lower Infliximab Levels and Increased Likelihood of Surgery in Pediatric IBD
Emil Chuang
Inflammatory Bowel Diseases, 2015
View PDFchevron_right
Biologic Therapies for Inflammatory Bowel Diseases
Vassilis Valatas
2013
View PDFchevron_right
Su1971 REAL-WORLD EFFECTIVENESS AND SAFETY OF USTEKINUMAB FOR THE TREATMENT OF CROHNS DISEASE: THE SCOTTISH USTEKINUMAB COHORT
jonathan macdonald
Gastroenterology, 2020
View PDFchevron_right